company background image
CATX logo

Perspective Therapeutics NYSEAM:CATX Stock Report

Last Price

US$12.66

Market Cap

US$893.4m

7D

-5.2%

1Y

371.0%

Updated

11 Oct, 2024

Data

Company Financials +

Perspective Therapeutics, Inc.

NYSEAM:CATX Stock Report

Market Cap: US$893.4m

CATX Stock Overview

Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.

CATX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Perspective Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Perspective Therapeutics
Historical stock prices
Current Share PriceUS$12.66
52 Week HighUS$19.05
52 Week LowUS$2.20
Beta1.44
11 Month Change-19.11%
3 Month Change-1.94%
1 Year Change370.98%
33 Year Change103.86%
5 Year Change308.39%
Change since IPO26.60%

Recent News & Updates

Recent updates

Shareholder Returns

CATXUS BiotechsUS Market
7D-5.2%1.1%1.0%
1Y371.0%20.8%33.6%

Return vs Industry: CATX exceeded the US Biotechs industry which returned 19.7% over the past year.

Return vs Market: CATX exceeded the US Market which returned 31.9% over the past year.

Price Volatility

Is CATX's price volatile compared to industry and market?
CATX volatility
CATX Average Weekly Movement9.7%
Biotechs Industry Average Movement9.7%
Market Average Movement6.3%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CATX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CATX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998118Thijs Spoorwww.perspectivetherapeutics.com

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.

Perspective Therapeutics, Inc. Fundamentals Summary

How do Perspective Therapeutics's earnings and revenue compare to its market cap?
CATX fundamental statistics
Market capUS$893.42m
Earnings (TTM)-US$52.16m
Revenue (TTM)US$1.46m

583.1x

P/S Ratio

-16.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CATX income statement (TTM)
RevenueUS$1.46m
Cost of RevenueUS$0
Gross ProfitUS$1.46m
Other ExpensesUS$53.63m
Earnings-US$52.16m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.77
Gross Margin100.00%
Net Profit Margin-3,562.98%
Debt/Equity Ratio0.5%

How did CATX perform over the long term?

See historical performance and comparison